Campanelli is the chairman of Endo Pharmaceuticals, and was, until recently, president and CEO of Endo Pharmaceuticals, where he led a turnaround focused on executing Endo's strategy to improve productivity, simplify their business, and increase the value of the company's US Branded, US Generics and international pharmaceutical assets.
He transformed the company through investments in high-barrier, technically challenging generic products and specialty brands--all with a laser focus on differentiated and intelligent product selection.
Earlier, Campanelli served as chief executive officer of Par Pharmaceutical Companies, Inc. following the company's September 2012 acquisition by TPG.
While CEO of Par, Campanelli built a strong leadership team and an industry-leading specialty pharmaceutical business with a diverse portfolio of complex generics and 505(b)2s.
Under Campanelli's direction, Par entered the sterile injectables segment via the JHP acquisition, positioning the company for future growth.
Notably, Par's sterile injectable segment ultimately grew from a baseline of zero to over USD 1bn in revenue during Paul's tenure at Par and Endo.
Campanelli's success in growing Par culminated in the acquisition of Par by Endo in 2015 for over USD 8bn.
Prior to Campanelli's tenure as Par's CEO, he served as COO and president of Par Pharmaceutical, Inc., the company's generics division.
Prior to joining Par, Campanelli served as vice president, Business Development at Dr. Reddy's Laboratories Ltd.
Slayback is a New-Jersey based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US